Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture

Author's Avatar
Dec 23, 2020
Article's Main Image

RICHMOND HILL, ON / ACCESSWIRE / December 22, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG ("CAIAC") for the Company's remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A. ("HIO"), for gross proceeds of PLN 6,700,000 (CAD $2,308,000).